

## ALKALOIDS FROM *HYDRASTIDIS CANADENSIS* AND THEIR CHOLINESTERASE AND PROLYL OLIGOPEPTIDASE INHIBITORY

HOŠŤÁLKOVÁ A.<sup>1</sup>, KUNEŠ J.<sup>2</sup>, MACÁKOVÁ K.<sup>1</sup>, HRABINOVÁ M.<sup>3</sup>, OPLETAL L.<sup>1</sup>

<sup>1</sup>ADINACO Research Group, Department of Pharmaceutical Botany and Ecology, Faculty of Pharmacy in Hradec Králové, Charles University in Prague

<sup>2</sup>Department of Inorganic and Organic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University in Prague

<sup>3</sup>Centre of Advanced Studies, Faculty of Military Health Sciences, University of Defence

e-mail: hosta4aa@faf.cuni.cz

### Introduction

Alzheimer's disease (AD) is one of the most prevalent causes of dementia. Treatment of this neurodegenerative disease is only symptomatic and targets single pathogenetic pathways. One of therapeutic approaches is application of central cholinesterases inhibitors alleviating cholinergic deficit in the brain (galanthamine, donepezil<sup>1</sup>). Acetylcholinesterase (AChE) cleaves acetylcholine to the basic components and maintains a metabolic balance. Cleavage of acetylcholine is an important factor for the regeneration of neuron. AChE inhibition has become a standard approach for AD treatment<sup>2</sup>. Butyrylcholinesterase (BuChE), which appears to substitute and supplement AChE function in the brain of AD patients, is a valuable target<sup>3</sup>.

Prolyl oligopeptidase (POP) is a cytosolic serine peptidase that hydrolyzes proline-containing peptides involved in the learning and memory processes, thus inhibitors could serve as supplementary treatment<sup>4</sup>.

*Hydrastis canadensis* L. (Ranunculaceae), also known as goldenseal, is perennial plant which grows wild in North America. The chief components are isoquinoline alkaloids, which can be divided into several structural types. The most abundant are protoberberine-type alkaloids: berberine (the main component), berberastine, canadine, corypalmine and isocorypalmine<sup>5</sup>. Further isolated alkaloids are: hydrastine, hydrastidine, isohydrastidine (phtalideisoquinoline-type), canadaline<sup>6</sup> and canadinic acid (secoberberine-type)<sup>7</sup>.

Berberine exerts potent AChE and BuChE inhibitory effect with IC<sub>50</sub> values ranging between 0.44–1.07 μM and 3.44–6.84 μM respectively<sup>8</sup> and also inhibits POP with IC<sub>50</sub> value of 145 μM<sup>1</sup>.

In the course of screening for natural cholinesterase inhibitors, we found that rhizome extract from *H. canadensis* showed promising AChE and BuChE inhibition activity with IC<sub>50</sub> value of 67.1 ± 11.3 μg/ml and 78.9 ± 11.3 μg/ml, respectively.

### Experimental methods

**General** – NMR: VNMR S500 spectrometer (Varian, Palo Alto, California, USA), CDCl<sub>3</sub> or CD<sub>3</sub>OD, 25 °C, 499.87 MHz for <sup>1</sup>H and 125.70 MHz for <sup>13</sup>C; MS (ESI): spectrometer LC/MS Thermo Finnigan LCQDuo (GenTech Scientific, Arcade, New York, USA) with electrospray ionization in positive mode and ion trap as analysator; optical rotatory power: polarimeter P3000 (A. Krüss Optronic, Hamburg, Germany).

**Materials** – Acetylthiocholine iodide (ATChI), butyrylthiocholine iodide (BuTChI), berberine chloride (> 95%), POP and its substrate, Z-Gly-Pro-p-nitroanilide (≥ 99%) were purchased from Sigma-Aldrich, galanthamine hydrobromide (> 98%) from Changsha Organic Herb Inc., and huperzine A (98%) from Tai'an zhonghui Plant Biochemical Co., Ltd. The red blood cell ghosts used as a source of AChE (HuAChE), and human plasma as a source of BuChE (HuBuChE) were prepared in our laboratory. For TLC, the development solvents used were mixtures of cyclohexane (cHx), toluene (To), chloroform (CHCl<sub>3</sub>), diethylamine (DEA) and ethanol (EtOH) (Penta, Ing. Švec, Praha, Czech Republic). Dry commercial goldenseal extract was obtained from the dealer Naturex (Wien, Austria). A voucher specimen is deposited at the Department of Pharmaceutical Botany and Ecology, Faculty of Pharmacy in Hradec Králové.

**Extraction and isolation** – 1033 g dry commercial goldenseal extract was exhaustively extracted with ethanol (EtOH) (96% v/v, 2×) by boiling for 30 min under reflux and the combined extract was filtered and evaporated to dryness under reduced pressure. The crude extract (0.3 kg) was acidified to pH Δ 1.5 with 2% hydrochloric acid (5.8 l), filtered and the filtrate was defatted with diethyl ether (3× 2 l). Solution was alkalized to pH 9–10 with 10% Na<sub>2</sub>CO<sub>3</sub> and exhaustively extracted with CHCl<sub>3</sub> (4× 8.6 l). The organic layer was evaporated to give 33.9 g of solid brown residue. For purification, the residue was treated with liquid-liquid extraction again. The extract (25.0 g), which was Dragendorff positive, was further fractionated by column chromatography on Al<sub>2</sub>O<sub>3</sub>, eluting with light petrol gradually enriched with CHCl<sub>3</sub> (80 : 20 – 0 : 100), and then CHCl<sub>3</sub> enriched with EtOH (99 : 1 – 80 : 20). Fractions of 250 ml were collected and monitored by TLC (To:CHCl<sub>3</sub>:EtOH:DEA 70 : 20 : 10 : 3; 1×), yielding 129 fractions which were combined into 3 fractions.

Preparative TLC (To:CHCl<sub>3</sub>:EtOH:DEA 70:20:10:3; 1×) of fraction **I** (0.976 g) gave two subfractions. Subfraction Ia was treated with preparative TLC (cHx:DEA 95:5; 1) to give compound **1**, crystallized from EtOH and CHCl<sub>3</sub> mixture (white crystals; 9.3 mg). Subfraction Ib was subjected to preparative TLC (cHx:DEA 95:5; 2×) to yield compound **2**, crystallized from EtOH (yellowish crystals; 424.1 mg). Fraction **II** (20.734 g) repeatedly crystallized from EtOH to give compound **3** (white crystals; 16.871 g). Fraction **III** (0.771 g) was chromatographed by preparative TLC (cHx:DEA 90:10; 2×), subfraction IIIb was subsequently treated with preparative TLC (To:CHCl<sub>3</sub>:DEA 75:25:5; 1×) to give compound **4**, which was crystallized from MeOH (yellowish crystals; 40.2 mg).

**Preparation of red blood cells ghosts; Acetylcholinesterase and butyrylcholinesterase assay; Prolyl oligopeptidase assay** – The same procedures were used as in our previous report<sup>10</sup>.

### Results and discussion

Extensive chromatographic purification led to isolation of four isoquinoline alkaloids (Figure 1), belonging to




Fig. 1. Structures of alkaloids isolated from *Hydrastis canadensis* extract

four structural types. Their structures were determined by comparison of their MS and NMR spectra and specific optical rotations with literature data. In the present study, we report the first full  $^1\text{H}$  and  $^{13}\text{C}$  NMR assignments and additional physical properties of 1-(6'-allyl-1',3'-methylenedioxybenzoyl)-3-chloro-5,6-dimethoxy-isoquinoline **1**:

$[\alpha]_{\text{D}}^{20}$  wasn't determined due to absence of chiral centre. white crystals; 9.3 mg

$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  8,06 (1H, s, H4), 8,01 (1H, d,  $J = 9,4$  Hz, H9), 7,37 (1H, d,  $J = 9,4$  Hz, H8), 7,20 (1H, dd,  $J = 17,3$  Hz,  $J = 11,0$  Hz, H18), 7,08 (1H, s, H14), 6,83 (1H, s, H17), 6,02 (2H, s, H20), 5,57 (1H, d,  $J = 17,3$  Hz, H19), 5,22 (1H, d,  $J = 11,0$  Hz, H19), 4,03 (3H, s H22), 4,02 (3H, s, H21).

$^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta$  193,8 (C11), 157,2 (C1), 152,1 (C7), 151,5 (C15), 146,7 (C16), 144,4 (C3), 140,8 (C6), 137,5 (C13), 135,8 (C18), 135,1 (C5), 129,2 (C12), 123,4 (C9), 121,0 (C10), 116,8 (C8), 116,2 (C19), 115,7 (CC4), 111,8 (C17), 107,5 (C14), 102,0 (20), 61,4 (C21), 56,6(C22).

MS (ESI positive)  $m/z$  (%): 398  $[\text{M}+\text{H}]^+$  (100), 380 (11), 340 (5)

These data are available only in Chinese in the patent item<sup>11)</sup>. In brief, the NMR assignments of (+)-canadoline **2**<sup>6)</sup>, ( $\pm$ )-hydrastine **3**<sup>12)</sup> and (–)-canadine **4**<sup>13)</sup> have been reported previously. Chlorine-substituted benzylisoquinoline-type alkaloid **1** was already isolated from *Thalictrum foliolosum* (Ranunculaceae)<sup>11)</sup>. An origin of this compound needs further exploration; it could be of native origin or arise from oxidation of native alkaloid in solution. Compounds **2–4** have been previously isolated from *H. canadensis* (Fig. 1).

All isolated compounds have been assayed for their human cholinesterase and POP inhibition activities (Table 1). Galanthamine hydrobromide, huperzine A and berberine were used as positive controls.

(+)-Canadoline exerts interesting activity against HuAChE and moderate activity against HuBuChE ( $\text{IC}_{50}$  values  $32.9 \pm 4.9 \mu\text{M}$  and  $105.4 \pm 15.6 \mu\text{M}$  respectively). Any of isolated alkaloids did not inhibit POP significantly.

(+)-Canadine isolated from *Corydalis cava* is significantly more potent HuAChE inhibitor<sup>14)</sup> than (–)-canadine from *Hydrastis canadensis*. These tetrahydroderivatives of berberine are less potent cholinesterase inhibitors. The structural requirements concerning cholinesterase are in connection with the planarity and rigidity of molecules in this case<sup>15)</sup>.

Compound **1** was not tested for its POP inhibition activity due to the isolation of insufficient amount. BuChE plays an important role in the late AD stages, when the level of AChE is declined by up 85% and BuChE represents the predominant cholinesterase in the brain<sup>16)</sup>.

## Conclusions

Isolated compounds were tested for their inhibitory activity against human cholinesterases and POP for first time. Compound **1** was tested for biological activity for second time so far.

In conclusion, the findings of this study indicate that major quaternary alkaloid berberine is probably

Table 1. HuAChE, HuBuChE and POP inhibition activity of the alkaloids isolated from *Hydrastis canadensis* extract

Alkaloid	HuAChE	HuBuChE	POP
		$\text{IC}_{50}^*$ ( $\mu\text{M}$ )	
<b>1</b>	$637.2 \pm 83.3$	$560.2 \pm 76.9$	n.d.
<b>2</b>	$32.9 \pm 4.9$	$105.4 \pm 15.6$	> 1000
<b>3</b>	$604.0 \pm 18.0$	$381.6 \pm 35.0$	> 1000
<b>4</b>	$637.2 \pm 83.3$	$560.2 \pm 76.9$	> 1000
<b>Reference compounds</b>			
Galanthamine	$1.7 \pm 0.1$	$42.3 \pm 1.3$	> 1000
Huperzine A	$3.3 \times 10^{-2} \pm 0.1 \times 10^{-3}$	> 1000	
Berberine	$0.7 \pm 0.1$	$30.7 \pm 3.5$	$142.3 \pm 21.1$
Z-prolyl-prolinal			$2.8 \times 10^{-3} \pm 2.2 \times 10^{-3}$

\* – results are the mean of six replications; n.d. – not determined due to limited material

responsible for cholinesterase inhibition of alkaloidal extract in the preliminary tests and there also was not any other alkaloid which would be more effective in POP inhibition.

Isoquinoline alkaloids are important for their wide spectrum of biological activities and still are of interest, although tertiary alkaloids from *H. canadensis* do not dispose inhibitory potency in term of human cholinesterases and POP.

#### Acknowledgements

This work was supported by grants SVV 260 063, Charles University grant Nr.204026/2012/UNCE, the European Social Fund and the state budget of the Czech Republic: TEAB Nr. CZ.1.07/2.3.00/20.0235 and the Grant Agency of the Czech Republic Nr. P303/11/1907.

**Conflicts of interest:** none.

#### References

1. **Jiráček R.** Farmakoterapie demencí. Prakt. Lékař. 2008; 4, 286–290.
2. **Lleó A.** Current therapeutic options for Alzheimer's disease. Curr. Genomics 2007; 8, 550–558.
3. **Orhan I. E.** Current concepts on selected plant secondary metabolites with promising inhibitory effects against enzymes linked to Alzheimer's disease. Curr. Med. Chem. 2012; 19, 2252–2261.
4. **García-Horsman J. A., Männistö P. T., Venäläinen, J. I.** On the role of prolyl oligopeptidase in health and disease. Neuropeptides 2007; 41, 1–24.
5. **McKenna D. J., Plotnikoff G. A.** Goldenseal (*Hydrastis canadensis*). In: Coates, P. M. ed. Encyclopedia of Dietary Supplements. 1st ed. New York: Marcel Dekker, Inc. 2005, 379–390.
6. **Messana I., La Bua R., Galeffi C.** The alkaloids of *Hydrastis canadensis* L. (Ranunculaceae). Two new alkaloids: hydrastidine and isohydrastidine. Gazz. Chim. Ital. 1980; 110, 539–543.
7. **Galeffi C., Cometa M. F., Tomassini L., Nicoletti M.** Canadine acid. An alkaloid from *Hydrastis canadensis*. Planta Med. 1997; 63, 194.
8. **Hyun Ah J., Byung-Sun M., Takato Y., Je-Hyun L., Yeong Shik K., Jae Sue C.** Anti-alzheimer and antioxidant activities of coptidis Rhizoma alkaloids. Biol. Pharm. Bull. 2009; 32, 1433–1438.
9. **Tarrago T., Kichik N., Segui J., Giralt E.** The Natural Product Berberine is a Human Prolyl Oligopeptidase Inhibitor. Chem. Med. Chem. 2007; 2, 354–359.
10. **Cahlíková L., Hrabínová M., Kulhánková A., Benešová N., Chlebek J., Jun D., Novák Z., Macáková K., Kuneš J., Kuča K., Opletal L.** Alkaloids from *Chlidanthus fragrans* and their acetylcholinesterase, butyrylcholinesterase and prolyl oligopeptidase activities. Nat. Prod. Commun. 2013; 8, 1541–1544.
11. **Hua H., Su Y., Ma D., Li S., Li D., Li J., Guo J.** Two chlorine-substituted benzyl isoquinoline alkaloids with antitumor activity separated from *Thalictrum foliolosum*. Faming Zhuanli Shenqing 2014; CN 103772366. apud Chemical Abstract 160, 730241.
12. **Herath W. H. M., Ferreira D., Khan I. A.** Microbial transformation of the phthalideisoquinoline alkaloid, (–)-β-hydrastine. Nat. Prod. Res. 2003; 17, 269–274.
13. **Janssen, R. H. A. M., Wijkens P., Kruk C., Biessels H. W. A., Menichini F., Theuns H. G.** Assignments of proton and carbon-13 NMR resonances of some isoquinoline alkaloids. Part 2. Phytochemistry 1990; 29, 3331–3319.
14. **Chlebek J., Macáková K., Cahlíková L., Kurfürst M., Kuneš J., Opletal L.** Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from *Corydalis cava* Schweigger. & Korte (Fumariaceae). Nat. Prod. Commun. 2011; 6, 607–610.
15. **Correché E. R., Andujar S. A., Kurdela R. R., Gómez Lechón M. J., Freile M. L., Enriz, R. D.** Antioxidant and cytotoxic activities of canadine: Biological effects and structural aspects. Bioorg. Med. Chem. 2008; 16, 3641–3651.
16. **Greig N. H., Lahiri D. K., Sambamurti K.** Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int. Psychogeriatr. 2002; 14, 77–91.